24/7 Wall Street
28 Jul 2026, 13:47 UTC · 4h ago
Intuitive Surgical Fell 37% to $355 With This Wall Street Pro Is Calling for $685
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
28 Jul 2026, 13:47 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Intuitive Surgical (ISRG) cut its full-year da Vinci procedure growth guidance to 13.5%-15.5%, down from 18% in 2025. — Guidance cuts on core growth metrics typically trigger significant valuation multiple compression and immediate share price declines.
-0.80ISRG management repurchased $379 million of stock in Q2 at an average price of $439, which is significantly above the current trading price of $356.83. — Insider/corporate buying at prices well above current levels signals strong management confidence in an undervalued asset.
+0.60The current share price of $356.83 represents a roughly 36% discount to the Wall Street consensus price target of $484.40. — A wide gap between market price and analyst consensus often creates a catalyst for a corrective rally if fundamentals stabilize.
+0.50Continue reading
6 related stories
Top 2 movers · tap to explore
U.S. procedure growth is decelerating due to GLP-1 usage reducing bariatric cases, ACA premium dynamics, and softness in China tenders. — These represent structural headwinds to growth that may not be quickly reversed, impacting the long-term bull thesis.
-0.40ISRG's recurring revenue now accounts for approximately 85% of total revenue ($2.47 billion), providing a stable financial base. — High recurring revenue reduces volatility and provides a safety net during periods of slowing system sales.
+0.30Which stocks this story touches
Positive mentions of FDA clearance for the Hugo platform and 78% growth in Cardiac Ablation.
Analysts remain constructive due to the Mako platform and Inari vascular deal.
Despite beating Q2 estimates and strong recurring revenue, the company faced an 11% share drop and 37% YTD decline due to lowered full-year guidance.
[mutual] Both are identified as large-cap med device peers in the surgical robotics peer group.
[mutual] Both companies compete in the surgical robotics market, specifically with the da Vinci and Hugo platforms.
[mutual] Both are identified as large-cap med device peers competing in the surgical robotics space.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
2h ago
